SCHEMBL30228153

SCHEMBL30228153

Cc1ccccc1-c1cc(=O)oc2cc(NCC(=O)OC(C)(C)C)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 4/20 0.53
▸ CA9 Q16790 4/20 0.53
▸ CA1 P00915 3/20 0.53
▸ ALB P02768 1/20 0.46
▸ MAOB P27338 1/20 0.46
▸ TDP1 Q9NUW8 2/20 0.45
▸ KCNA3 P22001 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ LMNA P02545 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ KDM4E B2RXH2 3/20 0.44
▸ HPGD P15428 3/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ NCOA1 Q15788 1/20 0.44
▸ NCOA3 Q9Y6Q9 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ RAB9A P51151 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30228426 0.86 ALDH1A1 (0.52) CA12CA9CA1ALBMAOB
SCHEMBL30228290 0.82 MAOB (0.49) CA12CA9CA1ALBMAOB
SCHEMBL30228310 0.82 CA12 (0.51) CA12CA9CA1TDP1KCNA3
SCHEMBL30228322 0.81 ALDH1A1 (0.42) CA12CA9CA1TDP1KCNA3
SCHEMBL30228596 0.80 IGLV6-57 (0.46) CA12CA9CA1KCNA3ALDH1A1
SCHEMBL30228425 0.79 ALDH1A1 (0.52) CA12CA9CA1TDP1KCNA3
SCHEMBL30228235 0.78 ALDH1A1 (0.48) CA12CA9CA1ALBMAOB
SCHEMBL30228128 0.78 CA12 (0.54) CA12CA9CA1ALBMAOB
SCHEMBL30228464 0.78 MAOB (0.62) CA12CA9ALBMAOBTDP1
SCHEMBL30228274 0.78 CA12 (0.70) CA12CA9CA1TDP1KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-10-23 — — US disclosed
WO-2023034346-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM CA12 4755/4885CA9 4824/4885CA1 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback